Figure 2.

Efficacy. (A) Individual patient RECIST response after 2 months of induction afatinib (n = 19). ND denotes lack of measurable disease by RECIST. Circles denote patients who were thought to be unresectable at study entry, but had dramatic responses to therapy and underwent surgery. Note: RECIST responses were not confirmed with a second scan as patients proceeded directly to chemoradiotherapy. ORR, objective response rate. (B) Distribution of pathologic response at time of surgery (n = 10 patients). Major pathologic response was defined as <10% residual tumor cells. (C) Progression-free survival of cohort. (D) Overall survival of cohort.